The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to Know

[1]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[2]  L. Gibson,et al.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. , 2009, The Cochrane database of systematic reviews.

[3]  S. Glück,et al.  A woman's heart , 2009, Cancer.

[4]  S. Reid-Arndt,et al.  Breast cancer and "chemobrain": the consequences of cognitive difficulties following chemotherapy and the potential for recovery. , 2009, Missouri medicine.

[5]  K. Albain,et al.  Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Goss.  Extending the benefits of adjuvant therapy in early HR+ breast cancer , 2008, Breast Cancer Research and Treatment.

[7]  J. Forbes,et al.  Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Costantino,et al.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Hadji.  Menopausal symptoms and adjuvant therapy-associated adverse events. , 2008, Endocrine-related cancer.

[10]  J. Forbes,et al.  Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Fabian,et al.  The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer , 2007, International journal of clinical practice.

[12]  P. Hadji.  Reducing the risk of bone loss associated with breast cancer treatment. , 2007, Breast.

[13]  C. Thorne,et al.  Management of arthralgias associated with aromatase inhibitor therapy , 2007, Current oncology.

[14]  S. Elliott,et al.  Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy , 2007, Current oncology.

[15]  R. Eastell,et al.  Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. , 2007, European journal of cancer.

[16]  S. Sereika,et al.  Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer , 2007, Menopause.

[17]  R. Riggins,et al.  Pathways to tamoxifen resistance. , 2007, Cancer letters.

[18]  Paul E. Goss.  Letrozole in the extended adjuvant setting: MA.17 , 2007, Breast Cancer Research and Treatment.

[19]  H. Greenlee,et al.  Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Manson,et al.  Estrogen therapy and coronary-artery calcification. , 2007, The New England journal of medicine.

[21]  H. Burstein.  Aromatase inhibitor-associated arthralgia syndrome. , 2007, Breast.

[22]  A. Localio,et al.  Modifiable risk factors for breast cancer recurrence: what can we tell survivors? , 2007, Journal of women's health.

[23]  E. Perez,et al.  Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[25]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  I. Zuna,et al.  Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. , 2006, The Lancet. Oncology.

[27]  P. Goss,et al.  Aromatase inhibitors and bone health in women with breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Lønning,et al.  Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. , 2006, European journal of cancer.

[29]  S. Fujiwara.  [Fracture risk assessment tool]. , 2006, Clinical calcium.

[30]  A. LaCroix,et al.  Statin use and breast cancer: prospective results from the Women's Health Initiative. , 2006, Journal of the National Cancer Institute.

[31]  C. Ritenbaugh,et al.  Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer , 2005, Cancer.

[32]  T. Whelan,et al.  Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[34]  N. Bundred,et al.  The effects of aromatase inhibitors on lipids and thrombosis , 2005, British Journal of Cancer.

[35]  E. Perez,et al.  The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  A. M. López,et al.  Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. , 2005, Archives of internal medicine.

[37]  Mitch Dowsett,et al.  Mechanisms of tamoxifen resistance. , 2004, Endocrine-related cancer.

[38]  F. Jänicke.  Are all aromatase inhibitors the same? A review of the current evidence. , 2004, Breast.

[39]  J. Cuzick,et al.  Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Shumaker,et al.  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. , 2004, JAMA.

[41]  Paul D. Miller,et al.  Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures , 2004 .

[42]  C. Aghajanian,et al.  Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. , 2004, Gynecologic oncology.

[43]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[44]  H. Rugo,et al.  The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. , 2003, Seminars in oncology.

[45]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.

[47]  P. Goss.  Breast cancer prevention—clinical trials strategies involving aromatase inhibitors , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[48]  J. Manson,et al.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[49]  A. Kriska,et al.  Physical activity levels before and after a diagnosis of breast carcinoma , 2003, Cancer.

[50]  B. Sherwin,et al.  Estrogen and cognitive functioning in women. , 2003, Endocrine reviews.

[51]  C. Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[52]  R. Penson,et al.  Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Rock,et al.  Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. , 1999, Journal of the American Dietetic Association.

[54]  T. Spector,et al.  A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.

[55]  K. Yaffe,et al.  Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.

[56]  P. Kelly,et al.  Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. , 1993, Bone and mineral.

[57]  H. Rugo,et al.  The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  J. Gligorov,et al.  Cardiovascular Safety Profiles of Aromatase Inhibitors , 2006, Drug safety.

[59]  P. Lønning,et al.  Plasma changes in breast cancer patients during endocrine therapy — lipid measurements and nuclear magnetic resonance (NMR) spectroscopy , 2004, Breast Cancer Research and Treatment.

[60]  K. Malone,et al.  Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.